JNJ 37822681

Drug Profile

JNJ 37822681

Alternative Names: JNJ-37822681

Latest Information Update: 18 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 18 Aug 2015 No recent reports on development identified - Phase-II for Schizophrenia in Slovakia, Bulgaria, Germany, Ukraine, Russia, Romania, Lithuania, Estonia, India, Taiwan, South Korea, Sweden, Belgium, South Africa and Malaysia (PO)
  • 16 Sep 2009 Pharmacodynamics and adverse events data from a phase I trial in Schizophrenia presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP-2009)
  • 11 Aug 2008 Preclinical trials in Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top